PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. completed its business combination with FS Development Corp. II, trading under the ticker FSII, through an 8-K filing dated December 30, 2021. The blank-check company was sponsored by an affiliate of Foresite Capital Management, a healthcare-focused investment firm, and conducted its initial public offering in 2021. The transaction brought Pardes Biosciences, a clinical-stage biopharmaceutical company developing antiviral therapeutics, into the public markets via the SPAC structure. The combined company operates in the life sciences and biotechnology sector. Visit SpacDesk and sign up for full filings, timeline data, and sponsor analytics on this and every other SPAC in the database.